210 related articles for article (PubMed ID: 37430437)
1. MRGPRX2, drug pseudoallergies, inflammatory diseases, mechanisms and distinguishing MRGPRX2- and IgE/FcεRI-mediated events.
Baldo BA
Br J Clin Pharmacol; 2023 Nov; 89(11):3232-3246. PubMed ID: 37430437
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MRGPRX2 but not FcεRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist.
Bawazir M; Amponnawarat A; Hui Y; Oskeritzian CA; Ali H
Front Immunol; 2022; 13():1033794. PubMed ID: 36275683
[TBL] [Abstract][Full Text] [Related]
3. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases.
Subramanian H; Gupta K; Ali H
J Allergy Clin Immunol; 2016 Sep; 138(3):700-710. PubMed ID: 27448446
[TBL] [Abstract][Full Text] [Related]
4. MRGPRX2-Mediated Degranulation of Human Skin Mast Cells Requires the Operation of G
Wang Z; Franke K; Bal G; Li Z; Zuberbier T; Babina M
Cells; 2022 Mar; 11(6):. PubMed ID: 35326404
[TBL] [Abstract][Full Text] [Related]
5. MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway.
Babina M; Wang Z; Roy S; Guhl S; Franke K; Artuc M; Ali H; Zuberbier T
J Invest Dermatol; 2021 May; 141(5):1286-1296.e4. PubMed ID: 33058860
[TBL] [Abstract][Full Text] [Related]
6. MRGPRX2 activation in mast cells by neuromuscular blocking agents and other agonists: Modulation by sugammadex.
Fernandopulle NA; Zhang SS; Soeding PF; Mackay GA
Clin Exp Allergy; 2021 May; 51(5):685-695. PubMed ID: 33275825
[TBL] [Abstract][Full Text] [Related]
7. GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells
Thapaliya M; Amponnawarat A; Tesmer JJG; Ali H
Front Immunol; 2022; 13():1032497. PubMed ID: 36275707
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones.
Elst J; Maurer M; Sabato V; Faber MA; Bridts CH; Mertens C; Van Houdt M; Van Gasse AL; van der Poorten MM; De Puysseleyr LP; Hagendorens MM; Van Tendeloo VF; Lion E; Campillo-Davo D; Ebo DG
Front Immunol; 2021; 12():668962. PubMed ID: 34385999
[TBL] [Abstract][Full Text] [Related]
9. MRGPRX2 activation as a rapid, high-throughput mechanistic-based approach for detecting peptide-mediated human mast cell degranulation liabilities.
Lafleur MA; Werner J; Fort M; Lobenhofer EK; Balazs M; Goyos A
J Immunotoxicol; 2020 Dec; 17(1):110-121. PubMed ID: 32525431
[TBL] [Abstract][Full Text] [Related]
10. Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2.
Zhang T; Che D; Liu R; Han S; Wang N; Zhan Y; Pundir P; Cao J; Lv Y; Yang L; Wang J; Ding M; Dong X; He L
Eur J Immunol; 2017 Nov; 47(11):1949-1958. PubMed ID: 28688196
[TBL] [Abstract][Full Text] [Related]
11. Cytokine Stimulation by MRGPRX2 Occurs with Lower Potency than by FcεRI Aggregation but with Similar Dependence on the Extracellular Signal-Regulated Kinase 1/2 Module in Human Skin Mast Cells.
Wang Z; Franke K; Zuberbier T; Babina M
J Invest Dermatol; 2022 Feb; 142(2):414-424.e8. PubMed ID: 34329659
[TBL] [Abstract][Full Text] [Related]
12. Emerging Roles for MAS-Related G Protein-Coupled Receptor-X2 in Host Defense Peptide, Opioid, and Neuropeptide-Mediated Inflammatory Reactions.
Ali H
Adv Immunol; 2017; 136():123-162. PubMed ID: 28950944
[TBL] [Abstract][Full Text] [Related]
13. GRK2 differentially regulates FcεRI and MRGPRB2-mediated responses in mast cells.
Thapaliya M; Ali H
Front Immunol; 2023; 14():1155777. PubMed ID: 37063868
[TBL] [Abstract][Full Text] [Related]
14. Inflamed Ulcerative Colitis Regions Associated With MRGPRX2-Mediated Mast Cell Degranulation and Cell Activation Modules, Defining a New Therapeutic Target.
Chen E; Chuang LS; Giri M; Villaverde N; Hsu NY; Sabic K; Joshowitz S; Gettler K; Nayar S; Chai Z; Alter IL; Chasteau CC; Korie UM; Dzedzik S; Thin TH; Jain A; Moscati A; Bongers G; Duerr RH; Silverberg MS; Brant SR; Rioux JD; Peter I; Schumm LP; Haritunians T; McGovern DP; Itan Y; Cho JH
Gastroenterology; 2021 Apr; 160(5):1709-1724. PubMed ID: 33421512
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide.
Dondalska A; Rönnberg E; Ma H; Pålsson SA; Magnusdottir E; Gao T; Adam L; Lerner EA; Nilsson G; Lagerström M; Spetz AL
Front Immunol; 2020; 11():559589. PubMed ID: 33101278
[TBL] [Abstract][Full Text] [Related]
16. Recent Knowledge and Insights on the Mechanisms of Immediate Hypersensitivity and Anaphylaxis: IgE/FcεRI- and Non-IgE/FcεRI-Dependent Anaphylaxis.
Ebo DG; Beyens M; Heremans K; van der Poorten MM; Van Gasse AL; Mertens C; Houdt MV; Sabato V; Elst J
Curr Pharm Des; 2023; 29(3):178-184. PubMed ID: 36284380
[TBL] [Abstract][Full Text] [Related]
17. Patient Characteristics Associated With Reactions to Mrgprx2-Activating Drugs in an Electronic Health Record-Linked Biobank.
Foer D; Wien M; Karlson EW; Song W; Boyce JA; Brennan PJ
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):492-499.e2. PubMed ID: 36356925
[TBL] [Abstract][Full Text] [Related]
18. MRGPRX2 and Adverse Drug Reactions.
McNeil BD
Front Immunol; 2021; 12():676354. PubMed ID: 34421893
[TBL] [Abstract][Full Text] [Related]
19. Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or "Innate Hypersensitivity"?
Spoerl D; Nigolian H; Czarnetzki C; Harr T
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28590439
[TBL] [Abstract][Full Text] [Related]
20. Cisatracurium induces mast cell activation and pseudo-allergic reactions via MRGPRX2.
Che D; Rui L; Cao J; Wang J; Zhang Y; Ding Y; Zhao T; Ma P; An H; Gao Z; Zhang T
Int Immunopharmacol; 2018 Sep; 62():244-250. PubMed ID: 30032049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
